Form 4: Upstream Bio CEO Granted Stock Options
SEC Form 4 Filing
Upstream Bio's CEO, Everett Rand Sutherland, was granted stock options for 500,000 shares of common stock on February 6, 2025, according to a Form 4 filing.
Summary
- A Form 4 filing with the SEC indicates that Everett Rand Sutherland, CEO of Upstream Bio, Inc., was granted stock options on February 6, 2025.
- The stock options give Sutherland the right to buy 500,000 shares of Upstream Bio's common stock at an exercise price of $8.53 per share.
- The options vest in 48 equal monthly installments starting February 6, 2025, contingent upon Sutherland's continued service.
- Allison Ambrose is acting as Attorney-in-Fact for Sutherland, signing the filing on his behalf.
- A substitute power of attorney was filed, appointing Allison Ambrose as substitute attorney-in-fact for multiple individuals, including E. Rand Sutherland, effective December 19, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The granting of stock options to the CEO can be seen as an incentive to align his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO.
- The CEO is incentivized to increase shareholder value through the stock option grant.
Key Dates
| Date | Description |
|---|---|
| 2024/10/10 | Date of original powers of attorney appointing Michael Gray as attorney-in-fact for listed individuals. |
| 2024/12/19 | Date of substitute power of attorney appointing Allison Ambrose as substitute attorney-in-fact. |
| 2025/02/06 | Date of the stock option grant to Everett Rand Sutherland. |
| 2025/02/06 | First vesting date for the stock options. |
| 2025/02/07 | Date of Form 4 filing. |
| 2035/02/05 | Expiration date of the stock options. |
Keywords
Form 4, stock options, Upstream Bio, CEO, Everett Rand Sutherland, beneficial ownership, Allison Ambrose, Attorney-in-Fact
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.